TJ
Therapeutic Areas
Shanghai RAAS Blood Products Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Human Albumin | Hypovolemic shock, burns, hypoalbuminemia | Approved |
| Human Immunoglobulin (IVIG) | Primary immunodeficiency, autoimmune diseases | Approved |
| Hepatitis B Immunoglobulin | Prevention of hepatitis B infection | Approved |
| Tetanus Immunoglobulin | Prophylaxis/treatment of tetanus | Approved |
| Rabies Immunoglobulin | Post-exposure prophylaxis of rabies | Approved |
| Human Coagulation Factor VIII | Hemophilia A | Approved |
| Human Prothrombin Complex Concentrate (PCC) | Bleeding disorders, reversal of anticoagulation | Approved |
| Human Fibrinogen | Congenital/acquired fibrinogen deficiency | Approved |
Leadership Team at Shanghai RAAS Blood Products
XY
Xie Yan
Chairman of the Board
HM
He Ming
Vice Chairman and President (CEO)
JD
Jiang Dejun
Director and Senior Vice President
TR
Tao Rui
Director and Senior Vice President
XZ
Xu Zhixiang
Director and Senior Vice President
ZB
Zhang Bo
Board Secretary and Vice President
TY
Tao Yimin
Chief Financial Officer (CFO)
TY
Tao Yijing
Vice President